Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
Patents for C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
11/2005
11/24/2005CA2565238A1 Amido compounds and their use as pharmaceuticals
11/24/2005CA2565026A1 Novel sustained-action bronchodilating agents for use in the treatment of respiratory diseases
11/24/2005CA2564489A1 Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity
11/24/2005CA2564027A1 1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones
11/24/2005CA2563607A1 4,5-disubstituted-2-aryl pyrimidines
11/24/2005CA2561859A1 Beta-carbolines useful for treating inflammatory disease
11/23/2005EP1598352A1 1-Glyoxylamide indolizines for treating cancer
11/23/2005EP1598340A1 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598339A1 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598338A1 1-(4-piperidinyl)-1,3-dihydro-2h-indole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1597261A1 Substituted amino heterocycles as vr-1 antagonists for treating pain
11/23/2005EP1597257A1 Oxazole-derivatives as ppar agonists
11/23/2005EP1597256A1 N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
11/23/2005EP1597246A2 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
11/23/2005EP1596860A2 Novel compounds
11/23/2005EP1596656A2 Pyrazoles and methods of making and using the same
11/23/2005EP1521809B1 Oxidation process for preparing quinacridone pigments
11/23/2005EP1296686B1 Praziquantel compositions for treating diseases caused by a coccidia
11/23/2005EP1280777B1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/23/2005EP1204638B1 Biphenyl-substituted cyclic keto enols as pesticides
11/23/2005CN1701069A 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases
11/23/2005CN1699350A Processes and intermediates for preparing anti-cancer compounds
11/22/2005US6967216 Neuropeptide Y receptor modulators; treating eating disorders
11/22/2005US6967215 Suitable for disinfection, deodorisation, and for the general and antimicrobial treatment of the skin and mucosa, and integumentary appendages (hair), especially for the disinfection of hands and wounds
11/22/2005US6967208 Anticoagulants; cardiovascular disorders
11/22/2005US6967205 Compounds with antibacterial and antiparasitic properties
11/22/2005US6967203 Use of pyridoindolone derivatives for preparing anticancer medicines
11/22/2005US6967199 Substituted diamine derivatives useful as motilin antagonists
11/17/2005WO2005108405A2 Lanthanide chelates and use thereof in bioanalysis
11/17/2005WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents
11/17/2005WO2005108399A1 Imidazopyridine compound
11/17/2005WO2005108398A1 6-substituted pyridoindolone derivatives production and therapeutic use thereof
11/17/2005WO2005108397A1 Substituted phenylamino-pyrimidines
11/17/2005WO2005108384A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
11/17/2005WO2005108368A1 Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
11/17/2005WO2005108367A1 Compounds for treatment of neurodegenerative diseases
11/17/2005WO2005108359A1 Novel compounds of proline and morpholine derivatives
11/17/2005WO2005107762A2 Certain chemical entities, compositions, and methods
11/17/2005WO2005095401A8 Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
11/17/2005WO2005072361A3 Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
11/17/2005WO2005070427A8 Compounds for the sustained reduction of body weight
11/17/2005WO2005051906A3 Heterocyclic inhibitors of mek and methods of use thereof
11/17/2005WO2004082602A3 Carboxamide spirohydantoin cgrp receptor antagonists
11/17/2005US20050256309 Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
11/17/2005US20050256180 drugs such as 1 -[4-(aminosulfonyl)phenyl]-8-{[(trifluoromethyl)sulfonyl]amino}-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide, used as antiinflammatory agents, antiarthritic agents, antipyretics or analgesics
11/17/2005US20050256151 3-(carboxy or carbamoyl)-5-amino-1H-pyrrolo(2,3-b)pyridines; cancer, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders; chemical libraries of these compounds
11/17/2005US20050256150 Enantioselective acyl transfer catalysts and their use in kinetic resolution of alcohols and desymmetrization of meso-diols
11/17/2005US20050256136 1-[2-(3-Ethyl-ureido)-3H-benzoimidazol-5-yl]-1H-imiazole-4-carboxylic acid methyl ester; bacteriostatic antibiotic; decrease antibiotic resistance of bacterial organisms; new class of compounds for bacterial infections
11/17/2005US20050256135 inflammatory, allergic, respiratory diseases; increased Histamine H3 receptor potency and reduced cardiovascular side effects; 1,6-naphthyridines or 1,7-naphthyridines; 6-pyrimidin-2-yl-2-(3-pyrrolidin-1-ylpropoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine
11/17/2005US20050256125 Selective inhibitors of certain receptor and non-receptor tyrosine kinases such as FAK (focal adhesion kinase); N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-4-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide for example; use with other antitumor agents
11/17/2005US20050256123 Heterocyclic inhibitors of MEK and methods of use thereof
11/17/2005US20050256109 HIV integrase inhibitors: cyclic pyrimidinone compounds
11/17/2005US20050256108 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension
11/17/2005US20050256104 Protease inhibitors
11/17/2005US20050256099 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
11/17/2005US20050256098 CGRP receptor antagonists
11/17/2005US20050256048 Selective androgen receptor modulators and methods for their identification, design and use
11/17/2005US20050255040 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
11/17/2005US20050253983 Providing solutions containing selected concentrations of soluble orienting compounds in an isotropic phase or in a lyotropic liquid-crystalline phase, introducing solutions into template having at least one dimension that is micro- or nanoscaled, removing sufficient solvent to form anisotropic solid
11/17/2005DE102004020908A1 Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen Substituted 5,6,7,8-tetrahydro-pyrido [4,3-d] pyrimidin-2-yl and 5,6,7,8-tetrahydro-quinazolin-2-yl compounds
11/17/2005CA2568241A1 Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
11/17/2005CA2566184A1 Imidazopyridine compound
11/17/2005CA2565843A1 Novel compounds of proline and morpholine derivatives
11/17/2005CA2565695A1 Certain chemical entities and compositions for use in the treatment of a cellular proliferative disease or disorder
11/17/2005CA2562561A1 6-substituted pyridoindolone derivatives production and therapeutic use thereof
11/16/2005EP1595881A1 Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
11/16/2005EP1595878A1 Indole derivatives with apoptosis inducing activity
11/16/2005EP1595871A2 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
11/16/2005EP1594873A1 Pyrrolidinohydrochinazolines
11/16/2005EP1594871A1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
11/16/2005EP1594870A1 Substituted indolepyridinium as anti-infective compounds
11/16/2005EP1594869A2 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
11/16/2005EP1594865A2 Antibacterial agents
11/16/2005EP1594860A2 Library of biphenyl derivatives useful for identifying compounds having both beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
11/16/2005EP1594849A2 Compounds, compositions, and methods
11/16/2005EP1461036A4 Bis hydrochloride monohydrate salt of rsv fusion inhibitor
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP1322161B1 Use of riboflavin and flavin derivatives as chitinase inhibitors
11/16/2005EP1317442B1 Quinolinone derivatives as tyrosine kinase inhibitors
11/16/2005EP1222182B1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
11/16/2005EP1218374B1 Pharmaceutically active sulfonamide derivatives
11/16/2005CN1227254C Pyridone compound and its prepn process
11/16/2005CN1227252C Process for preparation of 6-methyl-2-(4-methyl-phenyl)-imidazo [1,2-a] pyrimidine-3-(N,N-dimethyl-acetamide) and intermediates
11/15/2005US6965030 MAP kinase inhibitors; treating arthritis, ankylosing spondylitis, psoriatic arthritis, various gastrointestinal disorders; adult respiratory distress syndrome, asthma, COPD and Alzheimer's disease.
11/15/2005US6964971 Oral administering; sustained release
11/15/2005US6964970 Heterocyclic amines such as 2-benzoyl-1,3,4,9-tetrahydro-2H-pyrido(3,4-b)indole, used preferential inhibitors of fatty acid biosynthesis in bacterial systems; bactericides
11/15/2005US6964967 Substituted pyrido[2,3-d]pyrimidines and methods for their use
11/15/2005US6964966 Such as 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid for treatment of systemic or topical infections
11/15/2005US6964964 Anticancer agents
11/15/2005US6964957 For use in therapy of neurodegenerative diseases and certain cancers
11/15/2005CA2330351C New linear or cyclical ureas, their preparation process and the pharmaceutical compositions which contain them
11/15/2005CA2167183C Process for making hiv protease inhibitors
11/10/2005WO2005105814A1 Tetracyclic inhibitors of janus kinases
11/10/2005WO2005105805A1 Annelated carbamoylase-heterocycles, focused library, pharmaceutical compositions and methods for the production thereof
11/10/2005WO2005105802A1 Fused quinoline derivative and use thereof
11/10/2005WO2005105801A1 Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
11/10/2005WO2005105800A1 Enantiomer-pure hexahydro- pyrrolocyclopenta- pyridine derivatives
11/10/2005WO2005105799A1 Dialkoxy-imidazopyridines derivatives
11/10/2005WO2005105798A1 Substituted imidazo[1,2-a]pyridine compounds and drugs containing substituted imidazo[1,2-a]pyridine compounds
11/10/2005WO2005105797A1 Sulfonamides
1 ... 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 ... 646